July 26th 2024
The pre-approval pertains to a solid oral dose product that the CDMO will manufacture for a global pharmaceutical company.
Strategizing High-Wire, Multi-Indication Launches
February 14th 2024Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.